Item 8.01. Other Events.

On January 8, 2023, Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing topline data from its ongoing pivotal Phase 2 trial ("FIREFLY-1") of tovorafenib (DAY101) for pediatric patients with relapsed or progressive low-grade glioma and the Company updated guidance on the planned first patient dosing to the first quarter of 2023 for the Company's Phase 3 clinical trial (FIREFLY-2/LOGGIC) evaluating tovorafenib as a front-line therapy for patients newly diagnosed with pLGG.

Additionally, the Company has updated its corporate presentation in connection with its participation in the 41st Annual J.P. Morgan Healthcare Conference.

Copies of the press release and the updated corporate presentation materials are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.       Description

99.1          Press Release, dated January 8, 2023.

99.2          Corporate Presentation.

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses